Ribo Submits European Clinical Trial Application for Phase â… Study of INHBE-Targeting siRNA RBD3133
Suzhou Ribo Life Science (06938.HK) and its subsidiary Ribocure Pharmaceuticals AB (collectively referred to as "Ribo") ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results